Intravenous Dexamethasone Palmitate to Prevent Nausea and Vomiting After Brain Surgery Craniotomy

What this Trial Is About

Researchers are evaluating dexamethasone palmitate to prevent postoperative nausea and vomiting PONV in patients undergoing craniotomy. Although dexamethasone is commonly used for PONV prevention, some patients still experience symptoms within 24 hours after surgery. This trial assesses whether dexamethasone palmitate, which has a longer-lasting anti-inflammatory effect and fewer side effects, can improve PONV outcomes after craniotomy. Participants will be randomly assigned to one of two groups. One group will receive an intravenous injection of dexamethasone palmitate 8 mg, containing 5 mg dexamethasone after anesthesia induction and before the surgical incision. The other group will receive an intravenous injection of dexamethasone 5 mg at the same timing. Both treatments are given before the surgery begins to study their effects on PONV. During the study, participants will be monitored for PONV incidence within the first 24 hours and at 6, 24, 48, and 72 hours after surgery. Researchers will track nausea and vomiting episodes, severity of symptoms, use of rescue antiemetics, participant satisfaction, recovery quality, pain scores, length of hospital stay, and safety outcomes for up to one month postoperatively. This comprehensive monitoring will help evaluate the effectiveness and safety of dexamethasone palmitate compared to dexamethasone in preventing PONV after craniotomy.

Dexamethasone Palmitate for PONV After Craniotomy